Stefan Gradl retweeted
An off-topic question @AACR: In a world struggling with a climate crisis & the need to reduce energy consumption. Why is there the need to run air conditioning at maximum power in your lecture halls to bring them to freezing cold temperatures? #TravelingInAmerica #AACR23 – at Florida, USA
Stefan Gradl retweeted
A true highlight of #AACR23: Dennis Kirchhoff on behalf of my former colleagues @BayerPharma disclosing ATP-cooperative, highly selective, orally dosed #DGKzeta inhibitor #BAY2965501. Inhibition of this lipid kinase relieves an intracellular immune checkpoint in T & NK cells.
Very excited to see all of our colleagues from Bayer presenting their latest discoveries! Come listen to Dennis Kirchhoff at the NDotH session 1 disclosing the structure of our DGKz inhibitor bayer.com/media/en-us/bayer-…
Stefan Gradl retweeted
Our group of #BFBoundaryBreakers has grown by one outstanding Otto Bayer Award winner! @GloriusFrank @GloriusGroup from the @WWU_Muenster will be recognized for his cutting edge research - we are very much looking forward to hosting you in Leverkusen on Monday!
Stefan Gradl retweeted
Fellowships in Drug Discovery, Agricultural Science, and Medical Science. Apply from February 13th and become part of our #BFBoundaryBreakers! We support brilliant young scientists in life sciences with up to 10,000 € of #funding for up to 6 months abroad.
Stefan Gradl retweeted
After launching Vividion, Versant Ventures is back with what it calls a next-gen approach with Belharra Therapeutics. A $50 million Series A will kick things off for the small molecule developer.
endpts.com/vividion-2-0-ben-…
Stefan Gradl retweeted
A big part of Minh’s PhD is now out in @ACSCentSci
Here he unfolds how Minpp1 is one of the central proteins in the complex and intricate inositol phosphate signalling
Go check it out!
pubs.acs.org/doi/10.1021/acs…
Stefan Gradl retweeted
Here's the slide that took me 6 months to make. The six classes of molecular interactions for drug design. Clearly H-bonds are the first thing to master as a drug designer followed by pi-pi and sigma-sigma interactions.
Stefan Gradl retweeted
Congratulations to @michael_kathan for finally receiving well deserved recognition of your doctoral work from pre-Corona days. Yesterday the celebration finally took place - thanks to @Silicon_Martin, @Suessmuth_Lab & @BayerPharma for organizing a memorable event!
This Post is from an account that no longer exists. Learn more
Stefan Gradl retweeted
The eBook of Inducing Targeted Protein Degradation (Ed. @PhilippMCromm, published by @WileyVCH) is now available! Get yours today. Featuring a chapter by me and @ErikaMVAraujo. Print edition coming in December.
wiley.com/en-gb/Inducing+Tar…
Stefan Gradl retweeted
Check out this fantastic landscape overview of PI3K inhibitors in oncology by @LefrancJu ! What's been approved and what's coming among next-generation molecules including a PI3Ka degrader and isoform/mutant selective molecules.
Small Molecule PI3K Inhibition in Oncology: What's Been Done and What's to Come? | drughunters.com/3TBF6Gi
We reviewed the history and current status of PI3K inhibitors, including their approval history, resistance mechanisms, and the next generation of PI3K Inhibitors
Stefan Gradl retweeted
Our latest preprint lead by first author @JeremyAMMorgan. Take a look. Congrats to everyone involved in this study.
This Post is from an account that no longer exists. Learn more
Stefan Gradl retweeted
Happy to announce our joint publication is now online
BAY-069, a Novel (Trifluoromethyl)pyrimidinedione-Based BCAT1/2 Inhibitor and Chemical Probe pubs.acs.org/doi/10.1021/acs…
Stefan Gradl retweeted
Excited to share our latest preprint, where we used stable isotopomers of inositol to uncover novel inositol phosphate metabolites and their dephosphorylation sequences. Thanks to all our awesome collaborators! @JessenLab @SaiardiLab Keller Lab
biorxiv.org/cgi/content/shor…
Stefan Gradl retweeted
The Kusterlab is looking for a science manager. Apply now if you are interested in working with us!
Stefan Gradl retweeted
Check this out !
Applications to Nuvisan ICB's 1st Berlin MedChem Workshop on the 16th & 17th of June are now open! Final year PhD students and PostDocs within Europe who are interested in learning more about Medicinal Chemistry can apply until 28.02. 🧪#teamnuvisan
events.nuvisan.com/events/17…
Stefan Gradl retweeted
Are you a 4th year Ph.D. graduate student in the fields of organic synthesis, chemical biology, or computational chemistry? If so, we’re accepting applications for our annual Graduate Student Symposium in Chemical Research! Learn more here:
gene.com/careers/university-…
Stefan Gradl retweeted
Our Next #MedChemCASES is coming !! and it s a joint event with the @YoungSciNet . The webinar will be followed by a round table discussing the life as foreign scientist in Germany !! Register here : us06web.zoom.us/webinar/regi…
#webinar #medchem #research
PostDoc position at Bayer to discover new Radium chelators for alpha therapies
jobs.bayer.com/job/Berlin-Po…
Stefan Gradl retweeted
Congrats to @DirkTrauner on his ACS Cope Scholar Award!






























